Internal Competition Completed


Principal Investigators Selected
  • Patricia Finn is authorized to submit, Medicine

Program Summary

Program Summary

The program will support centers that integrate clinical and basic research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.  

 

Highly integrated and synergistic research programs are encouraged for the AADCRC program. This includes multi-institutional applications for conditions of interest to this FOA, especially where research resources are limited (e.g. non-allergic rhinitis or drug allergy). Research programs could be organized around either:

  • immunologic mechanisms/pathways that are hypothesized to be an important pathobiologic process in a condition of interest to this FOA, or
  • one or more clinical trials or clinical studies that test a novel therapeutic approach, mechanistic hypothesis or aim at elucidating disease phenotypes and endotypes in a condition of interest to this FOA.

NIAID programmatic priorities for this FOA are:

  • The role of innate and adaptive immune functions in the development and pathogenesis of asthma and allergic diseases with focus on severe asthma, chronic rhinosinusitis, atopic dermatitis and drug allergy;
  • The impact of the microbiome and pollution on immune responses as they pertain to the development, prevention and management of asthma, allergic rhinitis, food allergy and atopic dermatitis;
  • The interaction between infections and atopy and the role of immune responses to infections in the development and exacerbations of asthma, allergic rhinitis, chronic rhinosinusitis and atopic dermatitis;
  • Induction of and understanding of the mechanisms of desensitization and sustained tolerance for the treatment and prevention of asthma, allergic rhinitis, food allergy and drug allergy;
  • Genetic variations and epigenetic alterations affecting host immune responses to aeroallergens, food allergens and drug allergens;
  • Clinical, immunologic and physiologic phenotyping and endotyping of drug allergy, atopic dermatitis, chronic rhinosinusitis and non-allergic rhinitis syndromes.

Applications including the following types of studies will be considered non-responsive and will not be reviewed:

  • Research on autoimmunity and autoimmune diseases.
  • Research on primary immune deficiency diseases.
  • Demonstration and Education Research Projects.
  • Phase III clinical trials.
  • Clinical trials at foreign sites.
  • Continuation of ongoing (active) clinical trials. The applicant may only propose new clinical trials.  For the purpose of this FOA, a new trial is defined as one that has not previously recruited any subjects.
  • Applications in which human research is not the primary focus and does not constitute the clear majority of the proposed research.
  • Research on HIV or AIDS.

 

Funding instrument: Cooperative Agreement

Application Limits

Application Limits

University is limited to one proposal.

Additional Information

Deadlines

UIC Letter of Intent
February 14, 2017
UIC Internal Competition
TBD
Sponsor Letter of Intent
N/A
Sponsor Application
April 3, 2017

Letter of Intent

Letter of Intent

Letter of Intent (LOI) Form

 

Depending upon the number of LOIs submitted, OVCR might be required to facilitate an internal peer review process to select UIC’s submission(s) to this program.  White paper instructions will distributed to those who have submitted LOIs.

 

Please contact Natalia Glubisz at RDS@uic.edu or 312-996-8348 with any questions.

 

If an authorized principal investigator is not listed above, please consider the limited competition still open. Contact RDS@uic.edu for further information.